TRxADE HEALTH Inc. (MEDS) Financial Statements (2024 and earlier)

Company Profile

Business Address 2420 BRUNELLO TRACE
LUTZ, FL 33558
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 5122 - Drugs, Drug Proprietaries, and Druggists' Sundries (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments347461,1941,134322962
Cash and cash equivalents347461,1941,134322962
Receivables2,1257997087298501,019
Inventory, net of allowances, customer advances and progress billings3,02716112612076127
Inventory3,02716112612076127
Prepaid expense246389358111250364
Other undisclosed current assets116   875875
Total current assets:5,5482,0952,3862,0932,3733,347
Noncurrent Assets
Operating lease, right-of-use asset1,1889521,0021,0521,1001,147
Property, plant and equipment2886062656871
Intangible assets, net (including goodwill), including:14,5815905384511,0991,058
Goodwill 5,129     
Intangible assets, net (excluding goodwill)9,452     
Other undisclosed intangible assets, net (including goodwill)  5905384511,0991,058
Deposits noncurrent assets494949494949
Total noncurrent assets:16,1061,6501,6521,6172,3162,325
TOTAL ASSETS:21,6543,7454,0383,7104,6895,672
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1,7151,2408191,0191,0561,632
Accounts payable1,3298645167297441,195
Accrued liabilities386376303290312437
Debt5,230     
Derivative instruments and hedges, liabilities  1,957509   
Other liabilities4127922296810614
Due to related parties167167167
Other undisclosed current liabilities1,735274993893732733
Total current liabilities:9,0924,2632,5502,1472,0612,546
Noncurrent Liabilities
Long-term debt and lease obligation25     
Long-term debt, excluding current maturities25     
Liabilities, other than long-term debt9777778321,220938988
Due to related parties333  
Other liabilities  777832887938988
Operating lease, liability977     
Other undisclosed noncurrent liabilities     333333
Total noncurrent liabilities:1,0027778321,2201,2711,322
Total liabilities:10,0945,0403,3833,3673,3333,868
Equity
Equity, attributable to parent11,560(1,295)6557631,3991,821
Common stock000000
Additional paid in capital33,09020,58620,56020,48320,19320,112
Accumulated deficit(21,530)(21,880)(19,905)(19,720)(18,794)(18,291)
Equity, attributable to noncontrolling interest    (420)(42)(17)
Total equity:11,560(1,295)6553431,3571,805
TOTAL LIABILITIES AND EQUITY:21,6543,7454,0383,7104,6895,672

Income Statement (P&L) ($ in thousands)

12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
Revenues2,0582,2512,2482,5292,4003,279
Cost of revenue
(Cost of Goods and Services Sold)
(353)(606)(691)(986)(998)(2,108)
Gross profit:1,7051,6451,5571,5431,4021,171
Operating expenses(2,550)(1,990)(1,904)(3,488)(1,809)(2,274)
Operating loss:(845)(346)(347)(1,946)(407)(1,103)
Nonoperating income (expense)674(1,629)22643(122) 
Other nonoperating income   4138 
Interest and debt expense(252)(181)(62)(196)(130)(9)
Loss from continuing operations:(423)(2,156)(388)(1,499)(659)(1,112)
Loss before gain (loss) on sale of properties:(659)(1,112)
Loss from discontinued operations (3,354) (352)   
Other undisclosed net income25218162196130 
Net loss:(3,525)(1,975)(678)(1,303)(529)(1,112)
Net income attributable to noncontrolling interest    3782628
Net loss available to common stockholders, diluted:(3,525)(1,975)(678)(925)(503)(1,084)

Comprehensive Income ($ in thousands)

12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
Net loss:(3,525)(1,975)(678)(1,303)(529)(1,112)
Comprehensive loss:(3,525)(1,975)(678)(1,303)(529)(1,112)
Comprehensive income, net of tax, attributable to noncontrolling interest    3782628
Comprehensive loss, net of tax, attributable to parent:(3,525)(1,975)(678)(925)(503)(1,084)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: